-> pregabalin, an anticonvulsant, in development for epilepsy, neuropathic pain and other CNS disorders. This compound is minimally metabolized, making drug interactions unlikely. By the end of the year, the company will have initiated more than 25 clinical efficacy studies of this compound. They include trials in epilepsy, diabetic neuropathy, post-hepatic neuropathy, social phobia, anxiety disorder and acute/chronic pain.
->igmesine, a novel antidepressant that has demonstrated efficacy in Phase II trials for the treatment of major depressive disorder. Its unique mode of action offers the potential for a more rapid onset of action than current therapies with a favorable side effect profile.
->zenarestat, an aldose reductase inhibitor for the treatment and prevention of diabetic neuropathy. Licensed from Fujisawa, the therapy was shown in Phase II trials to limit and even reverse the nerve damage caused by diabetes.
->Metaret (suramin), a treatment for hormone refractory prostate cancer. In clinical trials, Metaret appears to be an effective treatment for the condition, decreasing pain scores and pain medication needs, and producing clinically significant reductions of the tumor marker PSA (Prostatic Specific Antigen). An NDA was filed at the end of 1997.
->CelexaTM (citalopram), a selective serotonin reuptake inhibitor, for the treatment of depression. A new drug application for CelexaTM was submitted by Forest Laboratories, Inc. to the U.S. Food and Drug Administration in May 1997. Warner-Lambert entered into an agreement with Forest Laboratories in March to co-promote the drug.
->avasimibe (CI-1011), an ACAT inhibitor, which prevents the accumulation of atherosclerotic plaque and reduces total cholesterol levels. In pre-clinical models, CI-1011 demonstrated a regression of arterial lesions. In addition, effective ACAT inhibitors may reduce total cholesterol levels by decreasing absorption of dietary cholesterol and reducing hepatic VLDL secretion. Phase III trials are expected to begin within a year.
->CI-1004, an anti-inflammatory that works by dual inhibition. It inhibits 5-lipoxygenase, the enzyme responsible for leukotrines, and it inhibits the cyclooxygenase, COX-2. This dual mechanism of action may provide advantages over COX-2 inhibition alone as a result of enhanced anti-inflammatory efficacy. CI-1004 could potentially have the GI safety of the new COX-2 agents with improved efficacy over current NSAIDS. Phase II trials for rheumatoid arthritis and osteoarthritis are expected to begin this year.
->CI-1001, (ethinyl estradiol/norethindrone acetate) an intravaginal ring, provides contraception for up to three months. A phase II trial showed good cycle control with excellent patient tolerance and acceptance. Phase III trials in both the U.S. and overseas are expected to begin in early 1999.
->FemHRT (ethinyl estradiol/norethindrone acetate) is a combination estrogen progestin hormone replacement therapy for use in treating osteoporosis and perimenopausal symptoms. The NDA is expected to be submitted in the U.S. within the next 12 months.
->clinafloxacin, a new generation quinolone anti-infective. This compound is effective against highly virulent bacteria, including those that are resistant to the most potent
drugs now available. The compound, for which oral and injectible forms are planned, will be for hospital use. An NDA is expected to be submitted later this year.
Those so called 10 products in WLA pipeline are either in advanced clinical development or are awaiting approval. Its not the entire pipeline. WLA entire pipeline i'm guessing is around 40-50 products. And FRX doesn't have only 1 drug in the pipeline. They have Celexa, awaiting approval for an Alzheimer's drug, and they've recently in-licensed 3 more compounds from HD Lundbeck. Other than those, I'm sure they've got more to show for their R&D spending as opposed to the 1 drug you believe them to have. Look a little closer next time JIMMY, maybe you'll get the right information.